Since TGFβ pathway-targeting reagents have been shown to have therapeutic effects on liver fibrosis, oxoglaucine appears to be a potential therapeutic drug for alleviating fibrosis. This evidence concerns the gene TGFB1 and Hepatic fibrosis.